Cassava Sciences said a study of its Alzheimer's treatment simufilam didn't meet co-primary, secondary and exploratory biomarker endpoints. Trading was halted at 7:25 a.m. ET and resumed trading at 8 ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

The findings from the study were presented at the AACR ... Accordingly, we expect the market sentiment surrounding the EXAS stock to remain positive surrounding this development.

He cited a study from the Budget Lab at Yale that estimated ... All of these factors lead Berezin to take a bearish view on the stock market. "Taken together, these considerations lead us to ...

However, Bristol Myers’ BMY stock was up 10.5% following ABBV’s news. The studies were designed to show a statistically significant reduction (improvement) in the change from baseline in the ...

If history is any guide, one stock market gauge suggests that Vice President Kamala Harris will defeat former President Donald Trump in the 2024 presidential race. In all but two elections since ...

Nvidia helped pull U.S. stock indexes higher after they stumbled in the morning on worries about escalations in the Russia-Ukraine war ...

Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Spero Therapeutics (NASDAQ:SPRO) stock tumbled 20% post-market after the company announced it was cutting its workforce by 39% in the wake of a failed Phase 2 study for its drug SPR720.